Evidence map›Paper›PMID 36366293›Full record

ArticleVaccines2022

Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination.

Chiara Dentone, Daniela Fenoglio, Marta Ponzano, Matteo Cerchiaro, Tiziana Altosole, Diego Franciotta, Federica Portunato, Malgorzata Mikulska, Lucia Taramasso, Laura Magnasco and 12 more

Abstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Chiara DentoneInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.
Daniela FenoglioDepartment of Internal Medicine, Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 16126 Genoa, Italy.ORCID 0000-0001-9532-6473
Marta PonzanoBiostatistics Unit, Department of Health Science, University of Genova, 16132 Genova, Italy.
Matteo CerchiaroInfectious Diseases Unit, Department of Health Science (DISSAL), University of Genoa, 16126 Genoa, Italy.
Tiziana AltosoleDepartment of Internal Medicine, Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 16126 Genoa, Italy.ORCID 0000-0002-8729-0834
Diego FranciottaAutoimmunology Laboratory, IRCCS Policlinico San Martino, 16132 Genoa, Italy.
Federica PortunatoInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.
Malgorzata MikulskaInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.ORCID 0000-0002-5535-4602
Lucia TaramassoInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.ORCID 0000-0002-6622-6358
Laura MagnascoInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.ORCID 0000-0002-6343-3271
Chiara UrasDepartment of Internal Medicine, Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 16126 Genoa, Italy.
Federica MagneInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.
Francesca FerreraDepartment of Internal Medicine, Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 16126 Genoa, Italy.ORCID 0000-0003-1172-5616
Graziana ScavoneBiotherapy Unit, IRCCS Policlinico San Martino, 16132 Genoa, Italy.
Alessio SignoriBiostatistics Unit, Department of Health Science, University of Genova, 16132 Genova, Italy.
Antonio VenaInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.
Valeria ViscontiLaboratory Unit, IRCCS Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0003-2647-0433
Gilberto FilaciDepartment of Internal Medicine, Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 16126 Genoa, Italy.ORCID 0000-0001-6445-8414
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.ORCID 0000-0001-7013-2250
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.ORCID 0000-0002-2209-5966
Antonio Di BiagioInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.ORCID 0000-0003-1436-5089
Matteo BassettiInfectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4M
Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. 75N93021C00NIAID NIH HHS 75N93021C00016
6 · The paper itself

Abstract

We prospectively studied immunological response against SARS-CoV-2 after vaccination among healthcare workers without (group A) and with previous infection (group B). The analyses were collected at T0 (before the BNT162b2), T1 (before the second dose), T2 and T6 (1 and 6 months after the second dose). For cellular immune response, the activation-induced cell marker assay was performed with CD4 and CD8 Spike peptide megapools expressed as Stimulation Index. For humoral immune response, we determined antibodies to Spike-1 and nucleocapsid protein. The linear mixed model compared specific times to T0. The CD4+ Spike response overall rate of change was significant at T1 (p = 0.038) and at T2 (p < 0.001), while decreasing at T6. For CD8+ Spike reactivity, the interaction between the time and group was significant (p = 0.0265), and the p value for group comparison was significant at the baseline (p = 0.0030) with higher SI in previously infected subjects. Overall, the anti-S Abs significantly increased from T1 to T6 compared to T0. The group B at T6 retained high anti-S titer (p < 0.001). At T6, in both groups we found a persistent humoral response and a high CD4+ T cell response able to cross recognize SARS-COV-2 variants including epsilon, even if not a circulating virus at that time.

Indexed as

cellular and humoral immune responsesSARS-CoV-2second dosevariants

Identifiers

PMID36366293
PMCPMC9697204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.